Zoetis Inc. Files 8-K Report

Ticker: ZTS · Form: 8-K · Filed: 2025-10-09T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, disclosure

Related Tickers: ZTS

TL;DR

Zoetis filed an 8-K, likely standard disclosures. No major news yet.

AI Summary

On October 9, 2025, Zoetis Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Zoetis Inc. is complying with regulatory requirements for reporting material information and financial updates to the public.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate adverse events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Zoetis Inc.?

The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported is October 9, 2025.

What is Zoetis Inc.'s state of incorporation?

Zoetis Inc. is incorporated in Delaware.

What is the IRS Employer Identification Number for Zoetis Inc.?

The IRS Employer Identification Number for Zoetis Inc. is 46-0696167.

What is the telephone number for Zoetis Inc.'s principal executive offices?

The telephone number for Zoetis Inc.'s principal executive offices is (973) 822-7000.

From the Filing

0001555280-25-000264.txt : 20251009 0001555280-25-000264.hdr.sgml : 20251009 20251009162408 ACCESSION NUMBER: 0001555280-25-000264 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251009 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251009 DATE AS OF CHANGE: 20251009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 251385341 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20251009.htm 8-K zts-20251009 0001555280 false 0001555280 2025-10-09 2025-10-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 9, 2025 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way Parsippany New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01. Regulation FD Disclosure. On October 9, 2025, the Company declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on December 2, 2025, to all holders of record of the Company’s common stock as of the close of business on October 31, 2025. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly i

View on Read The Filing